Benitec Biopharma Inc
BNTC12.790USD
+0.790+6.58%
收盤 11/07, 16:00（美東）報價延遲15分鐘
335.74M總市值
虧損本益比TTM
關於 Benitec Biopharma Inc 公司
Benitec Biopharma Inc 是一家臨牀階段的生物技術公司。該公司專注於新型基因藥物的開發。其專有的 Silence and Replace 脫氧核糖核酸 (DNA) 定向核糖核酸 (RNA) 干擾平臺將 RNA 干擾 (RNAi) 與基因療法相結合，創造出在單次施用治療構建體後同時促進致病基因持續沉默和野生型替代基因同時遞送的藥物。該公司正在開發基於 Silence and Replace 的療法 (BB-301)，用於治療包括眼咽型肌營養不良症 (OPMD) 在內的慢性和危及生命的人類疾病。BB-301 是一種基於腺相關病毒載體 (AAV) 的基因療法，旨在抑制致病基因的表達（減緩或停止疾病進展的潛在機制）並同時用正常的野生型基因替換突變基因。
Benitec Biopharma Inc簡介
公司代碼BNTC
公司名稱Benitec Biopharma Inc
上市日期Jul 11, 2012
CEODr. Jerel A. Banks, M.D., Ph.D.
員工數量16
證券類型Ordinary Share
年結日Jul 11
公司地址3940 Trust Way
城市HAYWARD
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94545
電話15107800819
網址https://benitec.com/
公司代碼BNTC
上市日期Jul 11, 2012
CEODr. Jerel A. Banks, M.D., Ph.D.
Benitec Biopharma Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
6.02K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Dr. Sharon Mates, Ph.D.
Dr. Sharon Mates, Ph.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
6.02K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Dr. Sharon Mates, Ph.D.
Dr. Sharon Mates, Ph.D.
Independent Director
Independent Director
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2023
FY2022
FY2021
FY2019
業務USD
名稱
營收
佔比
Licensing revenue
75.00K
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Licensing revenue
75.00K
0.00%
股東統計
更新時間: 10月22日 週三
更新時間: 10月22日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Suvretta Capital Management, LLC
37.62%
Janus Henderson Investors
11.06%
Franklin Advisers, Inc.
10.29%
Adage Capital Management, L.P.
7.51%
HBM Partners AG
3.97%
其他
29.54%
持股股東
持股股東
佔比
Suvretta Capital Management, LLC
37.62%
Janus Henderson Investors
11.06%
Franklin Advisers, Inc.
10.29%
Adage Capital Management, L.P.
7.51%
HBM Partners AG
3.97%
其他
29.54%
股東類型
持股股東
佔比
Hedge Fund
51.10%
Investment Advisor/Hedge Fund
25.61%
Investment Advisor
14.10%
Corporation
2.84%
Individual Investor
0.69%
Research Firm
0.22%
Bank and Trust
0.05%
Venture Capital
0.04%
Insurance Company
0.02%
其他
5.31%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
97
23.93M
91.18%
+1.50M
2025Q2
72
23.43M
89.26%
+3.16M
2025Q1
66
23.17M
88.28%
+2.93M
2024Q4
60
20.95M
89.36%
+4.31M
2024Q3
56
15.45M
85.62%
+7.92M
2024Q2
55
8.11M
85.06%
+2.49M
2024Q1
53
1.49M
56.66%
-268.80K
2023Q4
54
1.42M
56.57%
-342.85K
2023Q3
57
1.50M
61.34%
-154.56K
2023Q2
56
827.91K
52.26%
-194.13K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Suvretta Capital Management, LLC
9.88M
37.62%
--
--
Jun 30, 2025
Janus Henderson Investors
2.90M
11.06%
-16.16K
-0.55%
Jun 30, 2025
Franklin Advisers, Inc.
2.70M
10.29%
-159.28K
-5.57%
Jun 30, 2025
Adage Capital Management, L.P.
1.97M
7.51%
--
--
Jun 30, 2025
HBM Partners AG
1.04M
3.97%
+200.27K
+23.80%
Dec 31, 2024
The Vanguard Group, Inc.
969.17K
3.69%
+642.13K
+196.35%
Jun 30, 2025
Nantahala Capital Management, LLC
838.10K
3.19%
--
--
Jun 30, 2025
Nemean Asset Management, LLC
746.32K
2.84%
+648.12K
+659.98%
Apr 22, 2024
BlackRock Institutional Trust Company, N.A.
661.64K
2.52%
+477.75K
+259.80%
Jun 30, 2025
INFINITUM ASSET MANAGEMENT, LLC
500.00K
1.9%
+25.00K
+5.26%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Simplify Health Care ETF
0.87%
iShares Neuroscience and Healthcare ETF
0.61%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
Simplify Health Care ETF
佔比0.87%
iShares Neuroscience and Healthcare ETF
佔比0.61%
iShares Micro-Cap ETF
佔比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.02%
iShares Russell 2000 Growth ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
公告日期
類型
比率
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
